Last reviewed · How we verify
NCT04642183
Single In-Clinic Encounter With the Notal Vision Home OCT
trial in Neovascular Age-related Macular Degeneration in 70 participants. Completed in 30 September 2021.
24 August 2021
Quick facts
| Lead sponsor | Notal Vision Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 16 November 2020 |
| Primary completion | 24 August 2021 |
| Estimated completion | 30 September 2021 |
| Sites | 1 location across United States |
Conditions studied
- Neovascular Age-related Macular Degeneration — all drugs for Neovascular Age-related Macular Degeneration →
- Intermediate Age Related Macular Degeneration (Disorder) — all drugs for Intermediate Age Related Macular Degeneration (Disorder) →
Sponsor
Notal Vision Inc.
Who can join
18 and older, any sex, with Neovascular Age-related Macular Degeneration or Intermediate Age Related Macular Degeneration (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
this is a single In-Clinic Encounter With the Notal Vision Home OCT study. The study population will include up to 50 Age-related Macular Degeneration patients diagnosed with wet NV-AMD in at least one eye at the time of enrollment. All enrolled subjects should have at least one eye with active (wet) CNV (SRF and/or IRF) at the time of enrollment. All subjects will be enrolled at 1 site in the United States. in this study patients will be placed in a room with the Notal Vision Home OCT device and following a completion of a self tutorial will perform 3 unsupervised self-scans on each study eye (with a rest of \~5 minutes between self-scans). at the end of the testing sessions, the subject will be asked to complete subject user questionnaire.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
AI-based support for optical coherence tomography in age-related macular degeneration.
Mares V, Nehemy MB, Bogunovic H, Frank S, et al · · 2024 · cited 16× · PMID 38589936 · DOI 10.1186/s40942-024-00549-1
Verify or expand the search:
- PubMed search for NCT04642183
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neovascular Age-related Macular Degeneration
Currently open trials in the same condition.
- NCT07275840 — A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD · Phase 2 · recruiting
- NCT06847542 — A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD · Phase 3 · recruiting
- NCT07053358 — Safety and Efficacy Evaluation of LX111 Gene Therapy in nAMD Patients · EARLY_PHASE1 · recruiting
- NCT06680817 — A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study) · recruiting
- NCT06495918 — Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- R · Phase 3 · active not recruiting
Other Notal Vision Inc. trials
Trials by the same sponsor.
- NCT05690880 — ForeseeHome NRich Registry · active not recruiting
- NCT05745116 — Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT · unknown
- NCT05650047 — Home OCT Guided Management Study of Subjects Diagnosed With Neovascular-AMD · unknown
- NCT05417152 — Single In-Clinic Encounter With the Notal Vision Home OCT by DME Patients · completed
- NCT05202587 — The Evaluation of the Agreement Between the NVHO in the Automatic Fluid Quantification and Cirrus OCT · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04642183 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Notal Vision Inc.
- Last refreshed: 23 December 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04642183.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing